Agent for treating ophthalmopathy

Abstract

Use of the compound represented by general formula (I) for remedies of and protection against eye diseases is disclosed. General formula (I): (wherein, R 1 and R 2 independently represent a lower alkyl group, R 3 and R 4 independently represent a hydrogen atom or a lower alkyl group)

1 . A therapeutic agent for an eye disease containing the compound represented by the following general formula (I):  
       
         
           
           
               
               
           
         
       
       wherein, 
 R 1  represents a lower alkyl group,  
 R 2  represents a lower alkyl group,  
 R 3  represents a hydrogen atom or a lower alkyl group, and  
 R 4  represents a hydrogen atom or a lower alkyl group, as the active ingredient:  
 
     
     
         2 . The therapeutic agent for an eye disease containing the compound according to  claim 1  as the active ingredient wherein both R 1  and R 2  represent an ethyl group as well as both R 3  and R 4  represent a methyl group.  
     
     
         3 . The therapeutic agent according to  claim 1  or  2 , wherein the eye disease is glaucoma.  
     
     
         4 . The therapeutic agent according to  claim 1  or  2 , wherein the eye disease is a retinal disease.  
     
     
         5 . The therapeutic agent according to  claim 4 , wherein the retinal disease is retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, pigmentary retinal dystrophy or Leber's disease.